| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2015: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2014: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2013: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Outline of Final Research Achievements |
Fibroblast growth factor 2, FGF2 is a heparin binding protein that mediates numerous cell signaling. Previous study suggested that FGF2 is an also important inducer of osteoclastogenesis and angiogenesis in human and animal joint. This is a first investigation against murine model of RA using anti-FGF2 specific antagonist. We developed anti-FGF2 RNA aptamer, that binds human and mouse FGF2 and blocks the interaction between FGF2 and its receptor. The inhibition of FGF2-mediated signal proteins, cell proliferation and repression of OPG (osteoprotegerin) production was analyzed in cultured cells. Mice with GPI-induced rheumatoid arthritis used to assess efficacy. Administration of anti-FGF2 aptamer inhibited the development of arthritic in a dose-dependent manner. Significantly, anti-FGF2 aptamer slowed the progression of arthritis when administered after the onset of GPI induced arthritis.
|
